{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036410","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.423171+00:00","generated_at":"2026-06-04T08:09:43.423194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kyverna reports FY 2023 net loss of $60.4M; IPO raised $366.9M in Feb 2024","bullets":["Net loss $60.4M ($89.61/share) vs. $28.9M ($63.43/share) in FY 2022; cash burn $52.4M in operating activities.","Cash, equivalents and marketable securities $57.5M as of Dec 31, 2023; Feb 2024 IPO gross proceeds ~$366.9M.","Treated 14 autoimmune patients with KYV-101 CAR T therapy; FDA cleared Phase 2 trials in MS, MG and Phase 1/2 in systemic sclerosis.","Received FDA Fast Track Designations for KYV-101 in refractory MG, refractory progressive MS, and lupus nephritis.","Upcoming data releases at EULAR (Q2 2024), ECTRIMS (Q3 2024) and ACR (Q4 2024) for KYV-101."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036410","json":"https://secwatch.observer/filing/0000950170-24-036410.json","markdown":"https://secwatch.observer/filing/0000950170-24-036410.md","text":"https://secwatch.observer/filing/0000950170-24-036410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/0000950170-24-036410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/8k_for_earnings_release_.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:09:43.423194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e1f1438da6a03ff20909a670bf7e0bb9e23752df","claim":"Kyverna Therapeutics, Inc. reported the full year ended December 31, 2023 results: net income net loss of $60.4 million, or a net loss per common share of $89.61, EPS net loss per common share of $89.61.","evidence_excerpt":"For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a net loss of $28.9 million, or a net loss per common share of $63.43, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024036410/0000950170-24-036410-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"net loss of $60.4 million, or a net loss per common share of $89.61"},{"label":"EPS","value":"net loss per common share of $89.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}